Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ERSP process

This article was originally published in The Tan Sheet

Executive Summary

Parties involved in ERSP cases have the opportunity to participate in the review process under specific circumstances, counter to comments included in an article in the Oct. 16 issue of "The Tan Sheet" (1"The Tan Sheet" Oct. 16, 2006, p. 13). "Under ERSP's policies and procedures, the person or legal entity that initiates the inquiry has the option of actively participating in the review process, but is not required to do so," ERSP Director Peter Marinello tells "The Tan Sheet." When parties involved in cases choose to participate, they have access to all non-confidential submissions and can contribute comments to the record, Marinello says. However, "parties that elect to remain anonymous may not review the submissions or contribute to the case record," he adds...

You may also be interested in...

Demand Letters, NAD Review Can Check Firms’ Claims Without Court – Lawyer

Dietary supplement and nutritional product firms challenging competitors' claims have several options more cost-effective than litigation, advises Ivan Wasserman, a partner at Kelly Drye Collier Shannon (Washington, D.C.)

Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry

In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.

TytoCare Raised $50m In Funding Amid Rising Demand To Remotely Monitor COVID-19 Patients

TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts